Abstract | The use of nanoparticulate pharmaceutical drug delivery systems (NDDSs) to enhance the in vivo effectiveness of drugs is now well established. The development of multifunctional and stimulus-sensitive NDDSs is an active area of current research. Such NDDSs can have long circulation times, target the site of the disease and enhance the intracellular delivery of a drug. This type of NDDS can also respond to local stimuli that are characteristic of the pathological site by, for example, releasing an entrapped drug or shedding a protective coating, thus facilitating the interaction between drug-loaded nanocarriers and target cells or tissues. In addition, imaging contrast moieties can be attached to these carriers to track their real-time biodistribution and accumulation in target cells or tissues. Here, I highlight recent developments with multifunctional and stimuli-sensitive NDDSs and their therapeutic potential for diseases including cancer, cardiovascular diseases and infectious diseases. REVIEWS NATURE REVIEWS | DRUG DISCOVERY VOLUME 13 | NOVEMBER 2014 | 813
. The types of nano carriers that exist are diverse and include the following: liposomes; polymeric nanoparticles; polymeric micelles; silica, gold, silver and other metal nanoparticles; carbon nanotubes; solid lipid nanoparticles; niosomes; and dendri mers. The use of NDDSs can overcome several problems that are associated with traditional drugs, such as poor aqueous solubility, low bioavailability and nonspecific distribution in the body.
The first generation of NDDSs mainly aimed to address single challenges, such as the need to increase drug stability in vivo and the circulation time in the blood, or the need to target a drug to a specific tissue or pathology. Now, research has led to the development of NDDSs that can perform two or more functions (either simultaneously or sequentially) to overcome multiple physiological barriers to optimize delivery and deliver their loads (which can be single or multiple) to the required target sites (such as organs, tissues, cells) or specific pathologies in the body 3 (FIG. 1) . The properties of multifunctional NDDSs include the ability to bear a sufficient load of a drug or DNArelated material, have increased circulation times (through the use of soluble polymers) and target the intended site of action both nonspecifically (for example, via the enhanced permea bility and retention (EPR) effect) and specifically (via the attachment of targetspecific ligands). In addition, multifunctional NDDSs can respond to several stimuli that are characteristic of the pathological site, which is achieved through the inclusion of components that react to abnormal pH, temperature and redox condi tions, and to the overexpression of certain biological molecules. Multifunctional NDDSs can also respond to stimuli from outside the body, such as magnetic or ultrasound fields, and can be supplemented with an imaging contrast moiety to enable their biodistribution, target accumulation or the efficacy of the therapy to be monitored.
Although as yet there is no broadly recognized and accepted single classification system for multifunctional NDDSs, they can generally be divided into three groups. The first group consists of drugloaded NDDSs that com bine at least two different functions, such as longevity, targetability, stimulisensitivity or cell penetration. The second group of NDDSs, in addition to the previously described properties, are loaded with more than one drug and/or gene therapyrelated material, such as antisense oligonucleotides or small interfering RNAs (siRNAs).
Enhanced permeability and retention (EPR) effect
The property through which macromolecules (such as nanoparticles) accumulate in areas of inflammation including tumours, owing to the increased vascular permeability or abnormal blood vessel architecture. 
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Passive targeting
The mechanism through which nanoparticulate pharmaceutical drug delivery systems tend to accumulate in tumours, probably through the enhanced permeability and retention effect.
Quantum dots
Nanometrescale particles of semiconductor materials that have quantum mechanical properties.
Active targeting
The mechanism through which specific moieties attached to nanoparticulate pharmaceutical drug delivery systems force them to interact with a specific type of cell or tissue.
The third group consists of socalled theranostic NDDSs, which have an additional diagnostic label for use with current clinical imaging modalities.
Research in the area of multifunctional NDDSs 4,5 is very active, but substantial work remains to make them a clinical reality. Here, I highlight recent developments relating to multifunctional NDDSs. The majority of the currently available data relate to cancer, although there are some examples with other diseases.
NDDS longevity and targeting
One of the most common uses of NDDSs is to com bine prolonged circulation times with targetabilty. Such NDDSs are particularly useful for tumour targeting because tumours (as well as other inflammation zones) usually have increased vascular permeability as well as poor lymphatic drainage 6, 7 . This enables longcirculating NDDSs to accumulate in tumours through the EPR effect, which forms the basis for passive targeting 8 . Never the less, EPRbased drug delivery strategies face several challenges. First, tumours -especially large, solid tumours -are pathophysiologically heterogene ous. Some parts of such tumours are not vascularized, do not exhibit the EPR effect, may have sizeable necrotic areas 9, 10 and have varied microvascular permeability 10 . In addition, the increased interstitial pressure that exists within tumours may limit the EPRmediated accumula tion of NDDSs even if the vasculature is leaky 11 . NDDSs that are used for passive targeting and/or spontaneous accumulation must have long circulation times to ensure that sufficient drug is delivered to the tar get tissue. The usual approach to obtain longcirculating NDDSs is to coat them with hydrophilic and flexible polymers, such as poly(ethylene glycol) (PEG), as was first suggested for liposomes 12 . The pegylation of NDDSs prevents their interaction with opsonins and impedes their capture and clearance by the mononuclear phago cyte system. However, pegylated NDDSs can induce the production of antibodies that can accelerate the blood clearance of nanoparticles (as was demonstrated for clinically used pegylated liposomes), particularly after repetitive administration; this is the socalled accelerated blood clearance phenomenon 13, 14 . Although PEG is still the goldstandard polymer that is used to prepare longcirculating NDDSs, other hydrophilic polymers that are used include poly[N (2hydroxypropyl) methacrylamide] 15 , poly(acryloyl morpholine), polyNvinylpyrrolidones 16 and polyvinyl alcohol 17 . In general, the concept of pegylation, as well as the use of alternative polymers for longevity, is well established and reviewed; thus, in the next section only some of the key developments in this area are briefly mentioned. Importantly, the shape of NDDSs can also influence their pharmacokinetics and biodistribution 18, 19 . Liposomal longcirculating NDDSs are the most frequently studied type of NDDS; however, synthetic amphiphilic polymers have also been used to sterically stabilize several other types of NDDS to alter their bio distribution. For example, pegylation of gold nanoparti cles reduced their uptake by the mono nuclear phagocyte system and their subsequent clearance from the body 20 .
One potential application of pegylated gold nanoparticles is their use in photothermal tumour therapy (known as ablation) following their accumulation in the tumour 21 . Pegylated methotrexateconjugated polyllysine dendrimers also accumulated efficiently in solid tumours in rats and mice via the EPR affect 22 , and pegylation reduced the toxicity of positive chargebearing dendri mers in cellculture experiments 23 . Quantum dots can also be modified by pegylation. In mice, pegylated quantum dots had prolonged circulation times, which were attrib utable to their decreased uptake in organs (such as the spleen and liver) in which the mononuclear phagocyte system is active 24 . Active targeting of NDDSs can be achieved by attaching targeting ligands, such as monoclonal antibodies, trans ferrin, various peptides, folate, aptamers (singlestranded oligonucleotides) or certain sugar moieties, onto their surface 25, 26 . To prevent steric hindrance between the tar geting moiety and the protective polymer (such as PEG), the targeting ligand is usually attached to the chemically activated distal end of the NDDSgrafted polymeric chain 27 . An example of such active targeting of NDDSs is pegylated doxorubicinloaded liposomes that have human epidermal receptor 2 (HER2; also known as ERBB2)specific antibodies attached; these were suc cessfully used to target HER2overexpressing SKBR3 cells in mice 28 . A nucleosomespecific monoclonal antibody (mAb 2C5) that recognized multiple types of tumour cells via tumour cellsurfacebound nucleosomes improved the targeting of doxorubicinloaded liposomes to tumour cells and increased cancer cell cytotoxicity in in vitro and in vivo models 29 , including nude mice xeno grafted with the U87 cell line, which was derived from a human glioblastoma 30 . In another example of active targeting, pegylated gold nanoparticles conjugated to monoclonal F19 antibodies were used as targeted label ling agents for human pancreatic carcinoma tissues 31 . Lactoferrinconjugated PEG-polylacticacid nanoparti cles improved the delivery of the conjugated particles to the brain in an experimental murine model 32 . Figure 1 | Schematic of a drug-loaded, multifunctional, stimuli-sensitive NDDS. Drugs (Drug A and Drug B) can be loaded into a pharmaceutical nanocarrier, such as a liposome or polymeric micelle. Depending on the purpose of the nanoparticulate pharmaceutical drug delivery system (NDDS), various agents can be added to the nanoparticle to target the NDDS to a particular tissue, to increase cell penetration, to enable imaging or to release the drugs in response to a given stimulus. PEG, poly(ethylene glycol).
An interesting approach to increase targeting centres on selfassembling polyalkylcyanoacrylatebased nano particles. These types of nanoparticles could serve as pharmaceutical carriers for various drugs and could be produced in pegylated and 'activated' forms, enabling various ligands to be easily attached 33 . Polyisohexyl cyanoacrylate nanoparticles loaded with doxorubicin produced by BioAlliance Pharma as Livatag (doxoru bicin Transdrug) are currently in a Phase III trial in Europe and in the United States as a secondline treat ment of hepatocellular carcinoma after sorafenib, at a stage with no available approved treatment (Livatag press release; see Further information).
Aptamers that impart affinity and specificity by elec trostatic, hydrogen or hydrophobic bonding, but not via the base pairing, have also been used as stable and effi cient targeting moieties for NDDSs. For example, lipo somal NDDSs modified with specific aptamers have been used to target leukaemia cells 34 . Targetability can also be applied to stimulisensitive NDDSs. Gemcitabineloaded pegylated pHsensitive liposomes modified with an epidermal growth factor receptor (EGFR)specific antibody efficiently inhib ited tumour growth in mice 35 . Micellar NDDSs that were composed of amphiphilic conjugates of PEG and a copolymer of poly(εcaprolactone) and poly(malic acid) loaded with doxorubicin conjugated to poly(malic acid) via a pHsensitive bond were modified with folate for enhanced cellular uptake 36 . This preparation provided an enhanced release of doxorubicin at lowered pH values inside cancer cells 36 . NDDSs with similar properties based on pHsensitive polymethacrylate (PMA)grafted poly(amidoamine) nanocarriers and additionally pegylated and modified with a folate moiety efficiently delivered paclitaxel to tumours and inhibited tumour growth in mice 37 . Clearly, the separation of longcirculating NDDSs into those that achieve active targeting and passive targeting is conditional. That is, both phenomena are closely connected because NDDSs will accumulate in the target area via the EPR effect (passive targeting) before ligandmediated interaction with target cells (active targeting) occurs.
Another interesting issue is associated with the use of targeting ligands that are also naturally present (in their free form) in the circulation, such as folate, transferrin or certain peptides. Although one may expect competition between the ligands attached to NDDSs and the native ligands for the binding sites, the success of folate and transferrintargeted NDDSs (see below) demonstrates that this potential problem can be overcome. This is probably achieved through multipoint interactions of ligandmodified NDDSs with the target and/or because of the rapid recirculation of the cognate receptors, which provides sufficient opportunities for an interaction of the NDDS with the receptor.
Disease applications for NDDS-based therapies Cardiovascular diseases. NDDSs hold promise as thera peutic, diagnostic and theranostic agents for cardio vascular diseases 38 , particularly atherosclerosis 39 (FIG. 2) .
Multifunctional micellar NDDSs that combined a targeting pentapeptide, a fluorophore and a drug targeting atherosclerotic plaques by specifically binding to clotted plasma proteins were used to visualize atherosclerotic lesions in a mouse model. This preparation was shown to increase the amount of the anticoagulant agent biva lirudin that was delivered to the lesion 40 . Because the increased uptake of lowdensity lipoproteins (LDLs) by resident macrophages in plaques is associated with the progression of atherosclerosis, targeting plaque associated macrophages could be a method of inhibit ing LDL uptake 41 . Indeed, targeted polymeric NDDSs loaded with pravastatin specifically and dramatically inhibited the phagocytic activity of macrophages without affecting nontarget cells 42 . Multimodal diagnostic micellar NDDSs that were fluorescent and paramagnetic and targeted to macro phage scavenger receptors using specific antibodies have been used to visualize lesions in the abdominal aortas of mice with atherosclerosis 43 . Furthermore, polymeric NDDSs made of polyketals that were used to deliver smallmolecule drugs, such as the p38 mitogenactivated protein kinase (MAPK) inhibitor SB239063, and anti oxidant proteins, such as superoxide dismutase, to the area of the myocardial infarction in a rat model significantly improved cardiac function 44 . Liposomebased systems have also been frequently used to study the potential use of NDDSs in cardiovascular diseases 45 . For example, liposomes loaded with ATP or coenzyme Q accumulated well in the infarcted areas of the myocardium and improved cardiac parameters in rat and rabbit models of myocardial infarct 46, 47 . In a rat model of heart transplant, organ rejection was simulta neously imaged and treated using multifunctional poly meric NDDSs coloaded with superparamagnetic iron oxide nanoparticles (SPIONs) and plasmid DNA 48 . The SPION acted as a magnetic resonance imaging (MRI) contrast agent, whereas the plasmid DNA suppressed the local immune response 48 . NDDSs for targeted thromb o lytic therapy were developed by conjugating a throm bolytic agent (recombinant tissue plasminogen activator) to dextrancoated iron oxide nanoparticles, which were additionally modified with a thrombustargeted pep tide that was sensitive to activated factor XIII 49 . These NDDSs had increased binding to the margins of intravas cular thrombi and good thrombolytic activity in a mouse model of pulmonary embolism.
The translation of these NDDSs and others identified in similar studies into clinical practice remains the primary challenge to advancing the field and will be addressed in the closing section of this article.
Infectious diseases.
NDDSs have a growing role in com batting infectious diseases 50 . Of particular interest here are multicomponent NDDSs that contain metals, which can facilitate the formation of reactive oxygen species to eliminate pathogenic bacteria (FIG. 2) . For example, NDDSs that combined iodinated chitosan and silver nanoparticles bound to and killed bacteria better than either component alone 51 NDDSs can be used to deliver antibiotics inside cells; murine salmonellosis was successfully treated (with a greater than tenfold decrease in the level of pathogen in the liver and spleen of experimental mice) using gen tamicin in silica xerogelbased NDDSs 53 . The bacteria mediated degradation of a polyphosphoester core of antibioticloaded NDDSs by bacterial enzymes 54 pro vided an interesting example of a targeted, responsive NDDS. Nevertheless, this area is in early stages of devel opment and more animalbased studies will be required to reveal its full potential.
Cancer. The majority of preclinical research with NDDSs relates to cancer. Based on one of the most popular pharmaceutical nanocarriers -liposomes -several anticancer NDDSs are available at different stages of development (see TABLE 1 for a selected list).
The next step in the development of anticancer NDDSs is to target them to tumours. Cancer cells contain sev eral targets discussed below that can be used by NDDSs. Each of these targets could be specific for a certain type or types of cancer. Although it is possible that there will be overlapping expression of a target in cancer cells and normal cells, the level of expression is usually much higher in cancer cells; this characteristic is a prerequisite for an NDDStargeting ligand.
Folate has been used as a targeting ligand in pre clinical studies of NDDSs, owing to its easy conjugation to nanocarriers, high affinity for folate receptors and the lower expression of folate receptors in normal cells then in cancer cells and activated macrophages that are typical of inflammatory diseases 55 . Numerous folate targeted liposomal systems for cancer have been described (reviewed in REFS 56, 57) . For example, liposomes modi fied with folate via a PEG spacer efficiently delivered their cargo intracellularly through receptormediated endocytosis (which could bypass multidrug resistance), and doxorubicinmediated cytotoxicity against cancer cells expressing folate receptors was 85fold higher with drugloaded targeted liposomes than with unmodified liposomes 58 . In addition, when glutathioneconjugated folate was coupled to a PEG-distearoylphosphatidyl ethanolamine (PEG-DSPE) polymer and incorporated into the liposomal membrane, there was increased activity of the liposomal vincristine and favourable pharmaco kinetics in mice 59 . Folatebased modified NDDSs loaded with paclitaxel 60 or carboplatin 61 had high antitumour activity in mouse models. Liposome targeting to folate receptors has also been used to improve gene delivery of the herpes simplex virus type 1 thymidine kinase suicide gene; the liposome preparation inhibited tumour growth in a mouse model of oral cancer 62 . Transferrin, an 80 kDa serum glycoprotein, binds to the transferrin receptor and is taken into cells via receptormediated endocytosis. Compared with normal cells, the expression of transferrin receptor in certain cancer cells is much higher because of their increased demand for iron. Consequently, transferrinreceptor targeted NDDSs could be used for anticancer therapy. Indeed, this was demonstrated with doxorubicinloaded a | Nanoparticulate pharmaceutical drug delivery systems (NDDSs) can be engineered to target activated macrophages in atherosclerotic plaques or proteins present in a clot. These nanoparticles can thereby reduce plaque size through these two distinct mechanisms. b | NDDSs can be used to deliver metals to bacteria, where they can generate reactive oxygen species (ROS) to induce membrane blebbing and DNA damage. Antibiotics can also be delivered intracellularly using NDDSs.
longcirculating transferrinmodified liposomes in a rat model of liver cancer 63 . Other examples of the anticancer effects of transferrintargeted liposomes in mouse mod els include those loaded with boron compounds 64, 65 and with ceramide 66 . EGFRs are frequently overexpressed in solid tum ours 67, 68 and are therefore popular targets for NDDSs. HER2, which is overexpressed in approximately 20% of breast cancers 68 and some other cancers, is also a popular target for NDDSs. For example, there was greater accu mulation of HER2targeted pegylated liposomes loaded with doxorubicin than of nontargeted liposomes in HER2overexpressing breast cancer cells 69 and in ascitic lymphoma cells 70 .
The tumour vasculature is also an attractive target; destruction of the vasculature inhibits tumour growth and metastasis, it is not tumour typespecific and, importantly, NDDSs do not need to diffuse into the tumour mass to reach this target 71 . Targets that have been the focus of most studies include vascular endothe lial growth factor (VEGF; especially for antiangiogenic therapy), vascular cell adhesion molecule (VCAM), matrix metalloproteinases (MMPs) and integrins 72, 73 . For example, peptides that bind specifically to the tumour vasculature coupled to liposomes loaded with doxorubicin improved drug efficacy against several human cancers in severe combined immunodeficient mice 74 . Pegylated VCAMtargeted immunoliposomes bound selectively to activated endothelial cells in vitro and accumulated in tumour vessels in vivo 75 . MMPs are overexpressed on the newly formed vessels and tumour tissues, and are involved in tissue remodelling, tumour invasiveness, resistance to apoptosis and metastasis. An antigenbinding fragment of the antibody against MMP that was conjugated to doxorubicinloaded liposomes via a PEG spacer showed enhanced tumoural uptake and inhibited tumour growth in a mouse model 76 .
Considerations for NDDS receptor targeting. The success of receptormediated targeting depends strongly on the target affinity and the density of the receptors that are present on the cell surface. In addition, with pegylated NDDSs, the surfaceattached PEG could prevent or hinder the interaction between the targeting ligand and its recep tor. In a sense, this limits the opportunities of targeting because not all potential targets are expressed at sufficient levels. It is also important to consider, on a case by case basis, whether spontaneous targeting (passive accumula tion; based on the EPR effect) or ligandmediated specific targeting (which clearly requires more synthetic effort) is preferable. In general, if good accumulation of a drug in the pathological tissue is the primary goal, then EPR mediated accumulation may suffice. However, if the pres ence of the drug inside the cell is needed then ligands that can be internalized may be required.
Stimuli-sensitive NDDSs
The use of NDDSs that respond to different types of stimuli to control the properties and behaviour of the NDDS is an important and growing area of research 77 ( FIG. 3; TABLE 2 ). The stimuli can be internal and intrinsic to the target tissue (such as changes in pH, temperature, redox condition or the activity of certain enzymes) or external and artificially applied (such as a magnetic field, ultrasound and various types of irradiation) (FIG. 4) .
pH-triggered drug delivery. The acidic environment of tumours 78, 79 and endosomes can be harnessed in the design of stimulisensitive NDDSs. For example, an NDDS can contain pHsensitive components that pro tonate at lowered pH, resulting in the destabilization of the carrier and release of the drug. Pegylated poly lhist idine can form fairly stable polymeric micelles, but at pH values of approximately 6.5 and lower, histidine residues in the polyhistidine block become protonated, which results in an increase in the critical micelle con centration and micelle destabilization. As a result, the micelleincorporated drug is released 80 ; the high resultant drug concentration in the tumour interstitium or in the cytoplasm of the cancer cell may overcome drug efflux and other mechanisms of drug resistance 81, 82 .
To avoid the premature degradation of drugs in lyso somes, pHsensitive components (such as dioleoyl phosphatidylethanolamine (DOPE)) that are capable of destabilizing the endosomal membrane or rupturing endosomes are used to modify NDDSs (such as lipo somal NDDSs). This facilitates the fusion of the NDDS with the endovacuolar membrane after endocytosis and the subsequent release of the contents of the NDDS into the cytoplasm in response to the lowered endosomal pH 83 . Lipid conjugates of polyethyleneimine, such as DOPEmodified lowmolecularmass polyethyl eneimine (PEI; 1,800 Da), were used to prepare nanopar ticles to improve the PEImediated intracellular delivery of DNA 84 and siRNA 85 for various therapeutic purposes. Such conjugates have the combined advantages of posi tive charge, buffering capacity, fusogenicity and lowered toxicity.
The stimulus sensitivity of PEG coatings can enable the preparation of NDDSs with functions that are unveiled and activated only after the PEG molecules are detached. The use of ester and hydrazone moieties between the PEG moieties and NDDSs (which are stable at a neutral pH, such as in the blood, but hydrolyse at a pH of 6 or below) eliminates the protective effect of PEG during internalization by the target cell but also enables prolonged circulation in the blood. PEG is then removed once the NDDS is inside the acidified targets. PEG was detached from pHsensitive PEG-hydrazonephosphatidylethanolaminebased micelles and liposomes at lowered pH values, resulting in a cellular uptake that was similar to that of PEGfree NDDSs
86
.
Temperature-triggered drug delivery. Many pathological areas, such as tumours and inflamed areas, are hyper thermic 68 , which could be used as a possible trigger for stimulisensitive NDDSs. Alternatively, the tumour site could be heated from the outside to increase the size of pores within the microvasculature and increase blood flow, which results in an increased extravasa tion of drugloaded NDDSs. Lipids with a suitable geltoliquid phasetransition temperature are usually used to prepare thermosensitive liposomes, such as dipalmitoyl phosphatidylcholine or lysolipids. Indeed, temperaturesensitive lysolipid doxorubicinloaded liposomes (named ThermoDox) have improved effi cacy for liver cancertargeted drug delivery in mice 87, 88 and have also been tested in human patients. Celsion, which developed Thermodox, recently reported a 57% improvement in overall survival when heatactivated liposomal doxorubicin in combination with radio frequency ablation (RFA) was used in Phase III clinical trials to treat primary liver cancer (Celsion press release; see Further information). Temperaturesensitive NDDSs can also be prepared by incorporating polymers that have a lower physiological critical solution temperature (such as poly(Nisopropylacrylamide)) into the NDDS. In mice, it was shown that at temperatures above the low critical solution temperature, the polymer precipi tates and causes disruption of the NDDSs to release the drug 89 .
Redox-triggered drug delivery. The difference in redox potential between normal and tumour tissues, and between the intracellular and extracellular environ ment, can also be exploited for drug delivery in cancer. For example, the concentration of glutathione in cancer cells is 100 to 1,000fold higher than in the blood, and in a tumour mass the glutathione concentration is also markedly (100fold) higher than the extracellular level 5 . Reductionsensitive liposomes that have two forms of disulphideconjugated multifunctional lipids on their surface have been tested in a breast cancer cell line 90 . The cleavage of the disulph ide bond resulted in the removal of the hydrophilic head group of the conjugate, membrane reorganization and the release of encapsulated calcein 90 . The disulphide bond has been widely used as the cleavable and/or reversible linker in NDDSs to confer redox sensitivity.
Enzyme-sensitive systems. The increased expression of certain local enzymes in cancer, such as MMPs, could be considered as a biomarker for disease diagnosis and prognosis, as well as a means for the delivery of pharma ceuticals via an enzymetriggered mechanism 91, 92 (FIG. 2) .
Several substrates that are sensitive to MMPs have been designed for the delivery of drugs and as imaging agents. Cancerassociated proteases are another set of enzymes that are upregulated in tumours and can be used to develop enzymesensitive NDDSs. For instance, conjugates composed of cholesterol, peptide and poly acrylic acid were cleaved by a cancerassociated protease (urokinase) and induced rapid drug release in an in vitro model 93 .
Magnetically sensitive systems. NDDSs that can be mag netized either by incorporating magnetite or prepared by direct modification of magnetized metal particles with biocompatible polymers could be used for specific targeting under an external magnetic field. Unlike ferro magnetic materials, magnetite or ferromagnetic part icles that are less than 10 nm in diameter have a lower intensity of stray magnetic field, which reduces the potential health risks caused by magnetic fields 94 . These particles are referred to as SPIONs and can be surface modified with various biocompatible compounds, such as dextran, to reduce their aggregation and increase their biocompatibility 95 . SPIONs can be loaded into nanocarriers such as liposomes 94 , micelles 96, 97 or solid nanoparticles 98, 99 together with drugs and can increase drug localization in tumours under the exposure to a magnetic field. For example, liposomes coloaded with methotrexate and SPION 94 localized to tumours in mice. NDDSs contain ing SPIONs and a taxane drug could be additionally modified with PEG for longevity or with antibodies for tumour targeting 96 .
Control of NDDS functionalities with stimulus-sensitive moieties for enhanced targeting.
Multifunctional NDDSs that combine stimulussensitive properties with another drug delivery approach could improve the therapeutic outcome in animal models and, hopefully, in future clinical applications 86, 94, [100] [101] [102] [103] . The combined use of two different stimulussensitive approaches could be beneficial, as was shown for copolymeric micelles that were sensitive to both pH and redox potential. For example, doxorubicin delivery to HepG2 tumour cells by these dualsensitive NDDSs was more effective than with singlestimulussensitive control NDDSs 104 . Thermosensitive and magnet ically sensitive liposomes loaded with methotrexate had more favourable drug pharmacokinetic properties (that is, better drug accu mulation in skeletal muscle tissue in the tested animal model) than singlestimulussensitive delivery systems 94 . In addition, a multifunctional liposomal nanocarrier modified simultaneously with an antitumour mono clonal antibody (which actively targeted the tumour), a cellpenetrating peptide (which enabled intracellular delivery) and an MMP2sensitive PEG-lipid conjugate (which facilitated MMP2triggered PEG detachment from the lipid anchor) enhanced tumour targeting in vitro 105 . Of all the stimuli considered above, pH and temp erature (which can also be controlled by external factors) are the easiest to use among the intrinsic stimuli, whereas magnetic field and ultrasound -which are likely to be used clinically in the near future -are the external stimuli that are easiest to use. The use of redox condi tions or local enzymatic activity still requires substantial synthetic efforts, whereas lightbased approaches could be restricted primarily to superficial lesions unless fibre optics or nearinfrared irradiation can be used.
Intracellular delivery and organelle targeting
After reaching the target, NDDSs may still need to cross the barrier of the cell membrane to deliver their drug load into specific organelles within the cytoplasm. Several strategies to prevent lysosomal degradation following the cellular internalization of NDDSs have been described 106 , including the use of targeting and cellpenetrating moie ties as well as agents that can destabilize the lysosomal membrane, such as fusogenic lipids and poreforming proteins 107 . Cellpenetrating peptides are able to internalize nanosized particles, including liposomes, into cells [108] [109] [110] . Complexes of HIV TAT peptide (TATp)-liposomes and a plasmid encoding green fluorescence protein (pGFP) were used for successful in vitro transfection of several tumour and normal cells, as well as for the in vivo trans fection of Lewis lung carcinoma tumour cells in mice 111 . Octaargininemodified, bleomycin or doxorubicin loaded liposomes demonstrated good intracellular pene tration and strong inhibition of tumour growth in murine models 112, 113 . To provide intracellular drug delivery, the cellpene trating function should be shielded -for example, under a PEG coating -until the NDDS is inside the target cell (where PEG is cleaved by local conditions) 5, 86 . NDDSs such as targeted longcirculating pegylated liposomes and PEG-phosphatidylethanolaminebased micelles that possess several functionalities 86, 114 have been described. A pegylated TATpmodified pGFPloaded liposomal prep aration that had a PEG coating that detached at a lowered pH provided highly efficient transfection of tumour cells in vivo 115 . The potential therapeutic use of this approach was demonstrated in mice bearing ovarian cancer xeno grafts using a liposomal system that exposed a hidden cellpenetrating peptide (TATp) upon removal of PEG by the lower pH environment inside the tumour 116, 117 . Other micellarbased NDDSs were constructed using degradable εcaprolactonebased copolymers; the func tional group on the copolymer was used to incorporate siRNA against multidrug resistance protein 1 (MDR1; also known as ABCB1) or doxorubicin 118 . These micelles were also modified with the integrinspecific RGD4C peptide for cancer targeting and with the cellpenetrating TATp. Fluorescently labelled micelles were effectively taken up by cells and they improved drug delivery into cell nuclei, resulting in enhanced cytotoxicity in a mouse tumour model 118 . However, delivering drugs or drugloaded NDDSs inside cells may not be sufficient to achieve the maximum therapeutic response, and can even result in increased offtarget effects. As such, the delivery of drugloaded NDDSs directly to the organelle of interest could maxi mize the intended effect. This requires developing NDDSs that combine longevity, targetability and organ elle recognition. 
Theranostics
The simultaneous use of nanoparticulate pharmaceutical drug delivery systems for therapeutic as well as diagnostic and/or imaging purposes.
As mitochondrial dysfunction has been linked to many diseases, including cancer 119 , several strategies including the incorporation of the lipophilic cation rhodamine 123 to target NDDSs to mitochondria have been described 120 . Cell lysosomes have been targeted with NDDSs modified with octadecylrhodamine B 121 . Cytotoxic ceramides have been delivered to lysosomes of cancer cells using transferrinmodified liposomes, which resulted in reduced tumour growth in mice bearing an ovarian carcinoma xenograft 66 . Rhodamine Bmodified fusogenic liposomes have also been used to deliver gluco cerebrosidase into the mitochondria of Gaucher'stype cells with low glucocerebrosidase activity 122 . Glucocere brosidase is an enzyme that is deficient in patients with Gaucher's disease, and so this type of NDDS is of par ticular interest for the treatment of lysosomal storage diseases 122 .
NDDSs for multimodal imaging and theranostics Currently used medical imaging modalities include γscintigraphy, MRI, computed tomography and ultra sonography, together with some modifications of these methods. Because each modality has its own advantages and limitations, it is highly desirable to have more than one type of reporter group associated with the same NDDS. Multifunctional NDDSs have been constructed for multimodal imaging, which could overcome various problems associated with individual imaging modalities, such as insufficient sensitivity or resolution 123 . With this in mind, several NDDSs that combine optical imag ing with computed tomography or positron emission tomography (PET), or combine PET with computed tomography have been developed; these systems ena ble higher resolution and can be based on traditional NDDSs, such as liposomes or polymeric micelles, or they can use template nanoparticles with intrinsic contrast properties (such as gold or iron oxide nanoparticles, or quantum dots), which could be additionally modified with contrast moieties for other imaging modalities.
Thus, ironoxidebased nanoparticles have been modified using click chemistry with a nearinfrared dye to yield a dual MRI-nearinfrared contrast agent 124 . Pegylated liposomes coloaded with iohexol (a com puted tomography imaging agent) and gadoteridol (a Gdcontaining agent for MRI) had a long circula tion lifetime and enabled simultaneous enhancement of computed tomography and magnetic resonance signals in mice and rabbits 125 . Dualmode computed tomo graphy-MRI imaging in rats and mice was achieved using multifunctional Gdloaded dendrimerentrapped gold nanoparticles 126 . Simultaneous optical imaging, computed tomography imaging and MRI was made possible using liposomes labelled with a fluorophore tracer, 99m Tc, 111 In or 64 Cu and Gd 127, 128 in mouse models. Moreover, the addition of a radionuclide 129 enables the imaging system to become a therapeutic. The use of polychelating amphiphilic polymers, which enable the attachment of many reporter metal atoms and can be incorporated or absorbed onto the nanocarrier, enabled a marked increase in the number of bound reporter metal atoms per particle and imagesignal intensity 130 .
In mouse models, such preparations can be targeted to tumours with a cancerspecific mAb with rapid and specific tumour accumulation and could serve as effective contrast agents for MRI of tumours 131 . A relatively novel development in the area of multi functional NDDSs is the use of socalled theranostics; that is, the simultaneous use of pharmaceutical NDDSs for diagnostic and/or imaging purposes together with therapeutic use. Through the use of contrast reporter moieties, theranostics enable realtime monitoring of the biodistribution and target accumulation of NDDSs. Theranostics often use liposomes, polymeric micelles, dendrimers and iron oxide nanoparticles as the carrier component of NDDSs, and heavy metal atoms (such as 111 In , 99m Tc, Mn and Gd) as contrast moieties for γscintigraphy and MRI 132, 133 . For example, liposomes coloaded with quantum dots and the dopamine ago nist apomorphine had increased uptake into the brains of mice (apomorphine accumulation in the brain was increased by 2.4fold) and enabled fluorescent brain imaging 134 . Multifunctional receptortargeted nano complexes containing a neurotensintargeting peptide, DNA, a fluorophore and Gd have been used for brain imaging combined with DNA delivery in rats 135 .
Multifunctional coreshell polymeric nanoparticles composed of a poly(lacticcoglycolic acid) core and a positively charged glycolchitosan shell and coloaded with DNA and quantum dots enabled transdermal DNA delivery and transfection of epidermal Langerhans cells in mice, and allowed the migration of target cells to be monitored 136 . Longcirculating pegylated liposomes loaded with doxorubicin and additionally decorated with a tumourspecific antibody and contrast moie ties 137, 138 had increased therapeutic activity in vivo, and their target accumulation could be easily followed by γscintigraphy or MRI.
Ironoxidebased NDDSs, which combine magnetic drug targeting and MRI, have attracted attention in recent years. SPIONs (which are popular MRI imaging agents) are frequently combined with therapeutic agents 139 and PEG for longevity. For example, chlorotoxinconjugated iron oxide nanoparticles delivered therapeutic metho trexate and an MRI contrast agent to 9L glioma xenografts in mice 140 . Magnetic particles modified with a recombi nant peptide containing the aminoterminal fragment of urokinasetype plasminogen activator (uPA) can target tumours overexpressing uPA receptors, which enabled enhanced imaging and delivery in mice 141 . A targeted theranostic NDDS was prepared by covalent attachment of a nearinfrared imaging agent and a translocation pep tide to magnetic nanoparticles coloaded with siRNA and was used for multimodal tumour imaging and to moni tor the silencing activity of siRNA in tumour models 142, 143 . Furthermore, hydrophobic photosensitizers (such as protoporphyrin IX) were loaded into pHsensitive PEGpoly(βamino ester)block copolymer micelles for simul taneous tumour imaging and photo dynamic therapy in mice 144 . A pegylated, siRNAcontaining, magnetic resonancecontrast liposomebased NDDS that con tained fluorescent labels for histology downregulated the expression of survivin and inhibited tumour growth in xenografted tumours in mice 145 . In addition, pegylated liposomes that were loaded with Gd(III) for MRI, siRNA against survivin for tumour therapy, and additionally labelled with rhodamine-PE (phosphatidylethanolamine) for fluorescent detection have been studied in mice 145 . Targeting of theranostic NDDSs provides an addi tional advantage, as was shown for the codelivery of Gd and doxorubicin in liposomes targeted with a peptide specific for a neural cell adhesion molecule, which resulted in higher drug concentration in tumour tissues, increased inhibition of tumour growth and enhanced MRI visuali zation of Kaposi's tumours in mice 146 . Antibodymediated targeting of liposomes coloaded with iron oxide and doxorubicin to pancreatic tumours in mice enhanced both the antitumour activity and the tumour magnetic resonance signal compared with untargeted liposomes 147 . The combination of a chemotherapeutic drug and a con trast agent on the same NDDS facilitates the development of personalized nano therapeutic approaches because the efficiency of nanocarrier accumulation in the tumour (which is determined by the leakiness of the blood ves sels and traced by a technique that uses contrast, such as mammography) can assist in the determination of the correct dose of the therapeutic agent for the treatment of each individual tumour 148, 149 .
NDDSs for combination therapy
Drug combinations that can be delivered by NDDSs may be useful to combat drug resistance in patients with can cer 150 . A targeted liposomepolycationhyaluronic acid NDDS that codelivered three different siRNAs and one miRNA (to downregulate proliferation pathways, angio genesis and the cellular defence against apoptosis) into tumours resulted in an 80% decrease in tumour size in a mouse model of melanoma 151 . Pegylated liposomes modified with trilysinoyl oleyamide have been used to codeliver myeloid cell leukaemia 1 (MCL1)specific siRNA and the histone deacetylase inhibitor suberoxy lanilide hydroxamic acid into tumours, which resulted in a greater inhibition of tumour growth in mice bearing KB (human cervical cancer) xenografts 152 . Similarly, liposomes coloaded with doxorubicin and DNA encoding a dominant mutant form of survivin and targeted to tumours had enhanced antitumour activity in a murine model of Lewis lung carcinoma 153, 154 . Peptide targeted liposomes loaded with doxorubicin or cisplatin together with oligonucleotides against the molecules involved in two main drug resistance mechanisms, B cell lymphoma 2 (BCL2) and MDR1 (multidrugresistance protein 1), had high efficacy in human ovarian cancer xenografts 155 . Moreover, a combination of the colorectal cancer drug irinotecan and 5fluoroorotic acid in pegylated liposomes (at a 5:1 ratio) had synergistic effects and had higher therapeutic efficacy than did the free drug mixtures in animal models, including KBtumour bearing mice 156, 157 . For example, in a Phase I clinical trial, liposomes loaded with irinotecan and floxuridine liposomes (in a 1:1 molar ratio) were well tolerated and had antitumour activity in patients with advanced colo rectal cancer, whereby 13 out of 15 patients responded to therapy 158 . The drug is currently in Phase II (TABLE 1) .
Challenges in developing multifunctional NDDSs
When developing multifunctional and stimulisensitive NDDSs, one has to keep in mind that the different NDDSattached functions may affect the biological activity of those NDDSs differently. Thus, although tar geted ligands can result in improved cellular uptake, the surface properties, size and shape of the NDDSs will define their pharmacokinetics and biodistribution. Interestingly, some studies 159, 160 have demonstrated that the use of targeting ligands (that is, antibodies) does not necessarily increase the accumulation of NDDSs in the target area (with tumours as an example) when compared with EPRmediated accumulation. Instead, the targeting ligand may enhance intracellular drug delivery in situ ations in which an internalizable ligand was used 159, 160 , which could be beneficial for drugs that act intracellularly. It is also important to bear in mind that many surface attached functions (most notably targeting moieties) could compromise the increased longevity of NDDSs that is imparted by pegylation; the surface density of such ligands should be closely monitored to provide a desirable targeting effect without overly compromising longevity.
I have mainly considered findings from early preclini cal studies in this Review. The question then arises as to why, with so many interesting and impressive data, there still seems to be a long and arduous journey to bring these promising preclinical results into clinical practice? Potential answers to this question have been analysed in several recent publications [161] [162] [163] [164] . Based on these discus sions, one can first of all note that many data obtained in animal models cannot be easily translated into humans. This is particularly important in cancer research, in which subcutaneous tumour xenografts still represent the most frequently used model for targeted cancer therapy. Effective tumour targeting requires a sufficient number of productive contacts to be made between the targeted NDDSs and the target cells, which, in turn, requires effective preliminary accumulation of these NDDSs in the tumour via the EPR effect. In humans, this process is much more heterogeneous than in animal models because of a high heterogeneity in tumour blood flow. It is particularly problematic for animal models of subcu taneous tumours, in which the access of the blood to the tumour interstitium is greater than it is in solid tumours in patients. Unfortunately, the situation is even less clear with models of other noncancer diseases.
In addition, there is ongoing discussion as to whether passive or active targeting will be more beneficial for var ious potential therapeutic indications. Nevertheless, the current thinking suggests that passive spontaneous accu mulation of longcirculating NDDSs in tumours should be sufficient for drug delivery into the tumour mass, whereas intracellular drug delivery could be more effec tive if NDDSs are supplemented with specific targeting moieties that recognize cellsurface ligands to promote the internalization of drugloaded NDDSs. Moreover, many experimental models of various human diseases are not uniformly standardized, which often makes the comparison of results difficult. From a technological point of view, many of the effective and experimentally elegant NDDSs are difficult to reproducibly scale up in the industrial setting to produce NDDSs on a commercial scale because of their complexity, which will also add substantially to the final price of the product.
Assuming the problems described above are eventu ally resolved, the translation of the current knowledge into clinical applications will require the active involve ment of pharmaceutical and biotechnology companies and an increased understanding of the benefits of NDDSs by the broad clinical community. Once more clinical data become available, multifunctional, stimulisensitive and theranostic NDDSs will continue to be developed and improved. To become a successful product, such NDDSs should be reasonably simple. That is, their preparation should not require complex multistep processes, should not include uncommon or expensive constituents, and they should preferably be made of components that are generally recognized as safe. In the future, the scalability of NDDSs should not represent a problem and be prefer ably based on known and accepted processes and proto cols. The final product should also be sufficiently stable under normal storage conditions and easy to use; that is, it should not require complex administration protocols or regimens. If these requirements are met, multifunctional, stimulisensitive and theranostic NDDSs could become an important component of personalized therapy in the near future.
